Aspira Womens Health (STU:CUL) Quality Rank

View and export this data going back to 2020. Start your Free Trial

What is Aspira Womens Health Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Aspira Womens Health Quality Rank Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (STU:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (STU:CUL) » Definitions » Quality Rank

Comparable Companies

BIAF SLDX XGN OCX TRIB PMD STRR DMTK CHEK PCHM TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.